Drug Profile


Alternative Names: MP-513; Tenelia; teneligliptin hydrobromide hydrate

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Handok Inc; Mitsubishi Tanabe Pharma Corporation
  • Class Antihyperglycaemics; Ketones; Piperazines; Pyrazoles; Thiazolidines
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 01 Jan 2017 Handok Pharmaceuticals plans a phase I drug-drug interaction trial in Healthy volunteers in South Korea (NCT03009513)
  • 26 Sep 2016 Mitsubishi Tanabe Pharma plans a phase III trial for Type-2 diabetes mellitus in China (PO) (NCT02916706)
  • 01 Sep 2016 Phase-III clinical trials in Type-2 diabetes mellitus (Adjunctive treatment) in China (PO) (NCT02924064)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top